|
gptkbp:instanceOf
|
gptkb:protein
gptkb:drug
cytokine
|
|
gptkbp:administeredBy
|
gptkb:peginterferon_alfa-2a
ribavirin
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
1986
|
|
gptkbp:ATCCode
|
L03AB04
|
|
gptkbp:CASNumber
|
76543-88-9
|
|
gptkbp:contraindication
|
autoimmune hepatitis
severe psychiatric disorders
|
|
gptkbp:discoveredBy
|
gptkb:Hoffmann-La_Roche
|
|
gptkbp:drugClass
|
interferons
|
|
gptkbp:eliminationHalfLife
|
3-8 hours
|
|
gptkbp:hasMolecularFormula
|
C860H1353N229O255S9
|
|
gptkbp:hasUNII
|
P18A0J2Y9T
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
interferon alfa-2a
|
|
gptkbp:isGlycosylated
|
false
|
|
gptkbp:isRecombinant
|
true
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Roferon-A
|
|
gptkbp:mechanismOfAction
|
inhibits viral replication
modulates immune response
antiproliferative activity
|
|
gptkbp:molecularWeight
|
19269 Da
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:producedBy
|
gptkb:Bacteria
recombinant DNA technology
|
|
gptkbp:PubChem_CID
|
gptkb:DB00034
|
|
gptkbp:routeOfAdministration
|
intramuscular
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
gptkb:depression
gptkb:anemia
fatigue
neutropenia
thrombocytopenia
flu-like symptoms
|
|
gptkbp:target
|
gptkb:interferon_alpha/beta_receptor
|
|
gptkbp:usedFor
|
gptkb:chronic_myelogenous_leukemia
gptkb:hairy_cell_leukemia
gptkb:Kaposi's_sarcoma
gptkb:chronic_hepatitis_C
leukemia
chronic hepatitis B
|
|
gptkbp:bfsParent
|
gptkb:Roferon-A
|
|
gptkbp:bfsLayer
|
8
|